Aastrom Biosciences to Present at Multiple Conferences in April
April 09 2013 - 3:12PM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded multicellular therapies for the treatment
of severe, chronic cardiovascular diseases, today announced that
the company will be presenting at the following scientific and
investor meetings in April:
1st Annual Regen Med Investor Day
When: April 17, 2013
Where: Harmonie Club, New York, NY
Presentations:
- 9:00 a.m. EDT – Dr. Ronnda Bartel, chief scientific officer of
Aastrom, will participate in a panel discussion entitled "Clinical
Outlooks in Cardiovascular Disease."
- 1:45 p.m. EDT – Nick Colangelo, president and CEO of Aastrom,
will provide an overview of the company and its development
programs.
19th Annual International Society for Cellular Therapy
(ISCT) Meeting
When: April 22-25, 2013
Where: SKYCITY Auckland Convention Center, Auckland, New
Zealand
Presentations:
- April 23rd – Dr. Bartel will present "Commercialization
Strategies for Ixmyelocel-T, a Novel Autologous Therapy for Severe,
Chronic Cardiovascular Disease."
- April 24th – Poster presentation titled "Effects of
Ixmyelocel-T on Murine Bleomycin-Induced Lung Fibrosis."
- April 24th – Poster presentation titled "Phase 3 Readiness for
Autologous Cell Therapies: Unique Software Applications for
Training, Scheduling and Manufacturing of Ixmyelocel-T."
- April 25th – Dr. Kelly Ledford, scientist at Aastrom, will
present "Potential Atheroprotective Effects of Ixmyelocel-T
Cellular Therapy."
12th Annual Needham & Company Healthcare
Conference
When: April 30, 2013
Where: Westin Grand Central Hotel, New York, NY
Presentation: 10:00 a.m. EDT – Mr. Colangelo will provide
an update on the company's clinical programs and progress in
research and development.
About Aastrom Biosciences Aastrom Biosciences
is the leader in developing patient-specific, expanded
multicellular therapies for use in the treatment of patients with
severe, chronic cardiovascular diseases. The company's
proprietary cell-processing technology enables the manufacture of
ixmyelocel-T, a patient-specific multicellular therapy expanded
from a patient's own bone marrow and delivered directly to damaged
tissues. Aastrom has advanced ixmyelocel-T into late-stage
clinical development, including a Phase 2b clinical trial in
patients with ischemic dilated cardiomyopathy. For more
information, please visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and other filings with the Securities and Exchange
Commission. These forward-looking statements reflect management's
current views and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Media contact
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024